Podcast Index
Parcourez les podcasts par catégorie, ouvrez les épisodes récents et téléchargez l’audio pour l’écouter hors ligne.
BioCentury This Week
BioCentury
Your Daily Holiday Briefing
Checkiday.com
Il Caffettino di Mario Moroni
OnePodcast
Discover Crypto
HIT Network
游庭皓的財經皓角
游庭皓的財經皓角
The Instagram Stories - Social Media News
Daniel Hill, The Instagram Stories - Social Media News, YouTube, TikTok, Social Media News | Focusing on Instagram, Threads
ReadMultiplex.com Podcast.
Brian Roemmele
Alex Becker Channel
Alex Becker Channel
美股投資學-財女珍妮
財女Jenny
Larry Reidy’s America
larryreidy
Blockchain DXB
Blockchain DXB
Morning Wealth
THE STANDARD
The Kings Code Podcast
Tate
Mindset Reloaded - Brian Tracy Motivation Daily
Motiv
Dubai Property Podcast
Dubai Property Podcast
Complexity Premia
Coolabah Capital Investments
The Summit Red Deer Podcast
Summit Media
BBQ Interview Series - Kevin’s BBQ Joints
Kevin’s BBQ Joints
Accountants Daily Podcast Network
Momentum Media
Flash Stock Reports (Video)
Flash by StockSentinel.AI
David Seaman's Deep Podcast
David Seaman
Sam Talks Pizza and More
samtalkspizzaandmore
Lead Forward
Harvard Business manager
Energy vs Climate: How climate is changing our energy systems
Energy vs Climate | Produced by Amit Tandon & Bespoke Podcasts
商周Bar
商業周刊
Mother Tongue
Mother Tongue
Members Podcast
Marcus Today
И чо?
icho
It's Personal Stories, A Hospitality Podcast
David Kong, Dorothy Dowling, Rachel Humphrey, Lan Elliott
Heat Treated Garage
The Fellas
Let's Think About It Podcast
Morice Mabry | Executive Coach | Leadership Development
The Moneyball Channel
Donovan Scott
AI, en Dans på Roser
Dan Rose
DoubleBooked Official's Podcast
DoubleBooked Official
SANS Internet Storm Center's Daily Network Security News Podcast
Johannes B. Ullrich
SANS Internet Storm Center's Daily Network Security News Podcast
Johannes B. Ullrich
Global Economic Press
Global Economic Press
Business
BioCentury
New Parkinson’s disease programs aim to move beyond the historical norm of symptom management, branching into targeted therapeutics and cell therapies. On the latest BioCentury This Week podcast, BioCentury’s analysts re...
AbbVie's $10.9 billion deal to acquire Apogee will expand its immunology pipeline by delivering assets for atopic dermatitis and asthma. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the takeo...
Biotech IPOs that are getting out remain hot — but will that continue into the fall? On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the market for fresh biotech paper on NASDAQ, including the $...
Getting into the clinic fast to de-risk assets has become the name of the game in biotech, and at the academia-industry interface, too.From AI to NAMs to starting a Phase I trial in the U.S., BioCentury’s 3rd Grand Round...
FDA’s new leadership is sailing the agency into calmer waters amid a search for a permanent commissioner and permanent center directors. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdi...
Revolution Medicines continues to impress with more pancreatic cancer data, earning a standing ovation at ASCO over the weekend. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss the detailed data...
At ASCO among presentations focused on pancreatic cancer innovation beyond KRAS; however, abstracts for the cancer conference also highlight ADCs, bispecifics and diagnostics that are broadening the field’s approach to t...
Marty Makary wasn’t the only official on the outs at FDA last week in another tumultuous turn of events for the regulatory agency. On the latest BioCentury This Week podcast, BioCentury Washington Editor Steve Usdin disc...
China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer I...
Marty Makary’s hold on the top job at FDA is slipping, with White House leaks about President Donald Trump’s displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the lates...
UCB is the latest biopharma player to consummate a multibillion-dollar deal amid a surge in biotech M&A activity, acquiring Ken Song’s Candid Therapeutics, one of the leading T cell engager companies. On the latest BioCe...
More than 175 new oncology targets surfaced at this year’s American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make ...
Bispecific antibodies and dual-payload antibody-drug conjugates were in the spotlight at this year’s American Association for Cancer Research meeting in San Diego as biotechs unveiled their latest preclinical and first-i...
The past week has delivered the largest M&A deal ever for a private, venture-backed biopharma, the second-largest follow-on ever for a NASDAQ-traded biotech and what could soon become the largest biotech IPO ever on NASD...
A pathway proposed by FDA to cut the time it takes biopharma companies to get to first-in-human trials is more ambitious than similar policies in Australia, China and the U.K. On the latest BioCentury This Week podcast, ...
Biotech has been resilient as the financial markets teeter under global volatility. For now, M&A and financings, if not IPOs, are continuing, but will the Mideast conflict halt biotech’s recovery? On the latest BioCentur...
Biotech innovators around the world are finding speed to be the driver for investment and partnering — speed to early human data and speed to de-risk assets. The new momentum from Asia, in particular China, has added a f...
A flurry of deals, several with sizable upfront payments, has energized the biotech sector in March. On the latest BioCentury This Week podcast, BioCentury’s Paul Bonanos assesses last week’s deals by Merck, which is lay...
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss how the company has built...
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on NASDAQ — but will geopolitical tensions and war in the Middle East scut...
Remplissez le formulaire ci-dessous. Veillez à sélectionner à la fois Pays et Genres.
Envoyez-nous un message ci-dessous. Nous vous répondrons dans les 24 heures.